Advertisement

Picture EBD Group ChinaBio Partnering Forum 2020 Digital Event CBPF2020 650x80
Document › Details

CRISPR Therapeutics AG. (5/7/20). "Press Release: CRISPR Therapeutics to Present at the Bank of America Securities 2020 Health Care Conference". Zug & Cambridge, MA.

Organisations Organisation CRISPR Therapeutics AG (Nasdaq: CRSP)
  Group CRISPR Therapeutics (Group)
  Organisation 2 Bank of America Securities LLC (BofA Securities)
Product Product Bank of America Merrill Lynch Global Healthcare Conference 2020 VIRTUAL
Index term Index term CRISPR Therapeutics–Bank of America: investor conference, 202005 supply service CRISPR Tx presents at BofA Securities 2020 Health Care Conference
Person Person Kulkarni, Samarth (Sam) (CRISPR Therapeutics 201712– promoted CEO before CBO)
     


CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, is scheduled to present at the virtual Bank of America Securities 2020 Health Care Conference on Thursday, May 14, 2020, at 11:40 a.m. ET.

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.


About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc.CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.


Investor Contact:
Susan Kim
susan.kim@crisprtx.com

Media Contact:
Rachel Eides
WCG on behalf of CRISPR
617-337-4167
reides@wcgworld.com

   
Record changed: 2020-05-11

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for CRISPR Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81




» top